A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug combination as a possible treatment for endometrial
cancer.
The drugs involved in this study are:
- mirvetuximab soravtansine (IMGN853)
- pembrolizumab